Fredun Pharmaceuticals reported strong Q1 FY26 results with Net Profit increasing 63.82% to ₹6.77 Cr, and Total Income rising 52.08% to ₹119.86 Cr.

EBITDA also grew by 62.15% to ₹16.99 Cr.

This reflects successful execution of their growth strategy and strong demand for their diversified product range.

The company's order book stands at over ₹200 Cr, ensuring revenue visibility.

Strategically, its subsidiary acquired a controlling stake in One Pet Stop, expanding into the organized pet care market.

Further, the long-term credit rating was upgraded, underscoring improved financial standing.